{
    "nct_id": "NCT02770482",
    "title": "Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2020-06-18",
    "description_brief": "The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria. However, it can sometimes yield discordant results that are not discriminant (isolated variation in Ab42 or P-181 Tau). To answer this challenge, a new marker has been developed in recent years, namely amyloid beta-peptide 1-40 (A\u03b240). This marker reflects the patient's total amyloid deposits and is used to calculate the A\u03b242/A\u03b240 ratio. This ratio measures the relative variation of A\u03b242 as compared to the total amyloid burden. Literature data on this topic are sparse and to date, no report has been published evaluating the utility of this marker in the diagnostic strategy for AD.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "DIAGNOSTIC",
    "results": null,
    "target_category": "N/A",
    "drug": [],
    "placebo": [],
    "explanation_target": [
        "Reason: The description is a diagnostic/biomarker study evaluating cerebrospinal fluid amyloid beta\u2011peptide 1\u201140 (A\u03b240) and the A\u03b242/A\u03b240 ratio to improve interpretation of existing CSF markers (A\u03b242, total tau, p\u2011tau). This is an observational/diagnostic test evaluation, not an interventional drug trial \u2014 no therapeutic agent, mechanism of action, or symptom/cognition endpoint is described. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Act: I searched the literature to confirm the role of CSF A\u03b240 and the A\u03b242/A\u03b240 ratio in AD diagnosis. Multiple studies and reviews show that measuring A\u03b240 (or the A\u03b242/A\u03b240 ratio) improves diagnostic accuracy and reduces discordant CSF results compared with A\u03b242 alone (examples: validation of A\u03b240 assays and improved AUC/concordance with amyloid PET; large-sample analyses showing added value of A\u03b240 or the ratio). These references support that the trial description is diagnostic/biomarker work rather than a drug trial. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search2\ue202turn0search4\ue202turn0search6\ue201",
        "Reflect: Classification as 'N/A' (not applicable to the four therapeutic categories) aligns with the study aim \u2014 evaluating a biomarker (A\u03b240 / A\u03b242:A\u03b240 ratio) to improve diagnostic interpretation. No drug name, biologic, small molecule, cognitive enhancer, or neuropsychiatric intervention is present. Therefore 'N/A' is the correct category. Supporting sources from PubMed and specialty journals are cited above. \ue200cite\ue202turn0search2\ue202turn0search0\ue201"
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}